Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
13:43:53 EDT Mon 20 May 2024
Enter Symbol
or Name
USA
CA



Q:MNOV - MEDICINOVA INC - http://www.medicinova.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
MNOV - Q0.11.37·1.411.41.4011-0.0189-1.313.217441.42  1.42  1.352.66  1.2613:22:1406:0015 min RT 2¢

Recent Trades - Last 10 of 44
Time ETExPriceChangeVolume
13:22:14Q1.41-0.0114
13:20:52Q1.39-0.033
13:20:45Q1.40-0.025
12:54:53Q1.4011-0.0189100
11:55:35Q1.35-0.0756
10:56:21Q1.35-0.071,403
10:45:55Q1.38-0.046
10:45:37Q1.3523-0.067715
10:45:37Q1.3523-0.0677600
10:45:37Q1.3523-0.0677785

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2024-05-20 06:00U:MNOVNews ReleaseMediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Prevention of Metastasis of Eye Cancer
2024-05-14 06:00U:MNOVNews ReleaseMediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Treatment of Chlorine-Induced Acute Respiratory Distress Syndrome
2024-05-07 06:00U:MNOVNews ReleaseMediciNova Receives Issue Notification for New Patent Covering Extended-Release Formulations of MN-166 (ibudilast)
2024-04-02 19:00U:MNOVNews ReleaseMediciNova Announces Abstract Regarding Results of a Clinical Trial of MN-166 (ibudilast) in Glioblastoma Accepted for Presentation at the 2024 American Society of Clinical Oncology Annual Meeting (2024 ASCO)
2024-03-26 19:00U:MNOVNews ReleaseMediciNova Receives a Notice of Allowance for a New Patent Covering MN-166 (ibudilast) for the Treatment of Macular Injury in Japan
2024-03-20 19:00U:MNOVNews ReleaseMediciNova Announces Two Abstracts regarding MN-001 (tipelukast) and MN-002 Accepted for Presentation at the 92nd EAS 2024 Congress, the Annual Meeting of the European Atherosclerosis Society
2024-03-12 06:30U:MNOVNews ReleaseMediciNova Announces New Data and Results of MN-166 (ibudilast) in Chlorine Gas-induced Acute Lung Injury Presented at the 63rd Annual Meeting of the Society of Toxicology
2024-01-17 06:00U:MNOVNews ReleaseMediciNova Receives a Notice of Grant for a New Patent Covering MN-166 (ibudilast) for the Treatment of Macular Injury in China
2023-12-21 18:00U:MNOVNews ReleaseMediciNova Announces Abstract Regarding MN-166 (ibudilast) in Chlorine Gas-induced Lung Injury Accepted for Presentation at the 63rd Annual Meeting of the Society of Toxicology
2023-12-06 18:00U:MNOVNews ReleaseMediciNova Receives a Notice of Decision to Grant for ‚  a New Patent Covering MN-166 (ibudilast) for the Treatment of Progressive MS in Europe
2023-11-19 18:00U:MNOVNews ReleaseMediciNova Announces New Data and Results of a Phase 2 Clinical Trial of MN-166 (ibudilast) in Glioblastoma Presented at the 28th Annual Meeting of the Society for Neuro-Oncology
2023-10-27 01:00U:MNOVNews ReleaseMediciNova ¢ € ™s Collaborator Initiates Clinical Development of a Gene Therapy Product for the Treatment of Phenylketonuria
2023-10-10 19:00U:MNOVNews ReleaseMediciNova Receives a Notice of Allowance for ‚  a New Patent Covering the Combination of MN-166 (ibudilast) and Riluzole for the Treatment of Amyotrophic Lateral Sclerosis (ALS) in Canada
2023-10-04 19:00U:MNOVNews ReleaseMediciNova Receives Gene Therapy Milestone Payment
2023-09-27 19:00U:MNOVNews ReleaseMediciNova Announces Results of Studies under BARDA Contract to Develop MN 166 (ibudilast) as a Medical Countermeasure Against Chlorine Gas-induced Lung Injury
2023-08-17 19:00U:MNOVNews ReleaseMediciNova Announces Abstract Regarding MN-166 (ibudilast) in Glioblastoma Accepted for Presentation at the Annual Meeting of the Society for Neuro-Oncology
2023-08-16 19:00U:MNOVNews ReleaseMediciNova Receives a Notice of Intention to Grant for ‚  a New Patent Covering MN-166 (ibudilast) for the Treatment of Macular Injury in Europe
2023-08-15 19:00U:MNOVNews ReleaseMediciNova Receives a New Patent Covering MN-001 for the Treatment of Scleroderma and Systemic Sclerosis in Europe
2023-08-14 19:00U:MNOVNews ReleaseMediciNova Receives a Notice of Intention to Grant for a New Patent Covering MN-001 and MN-002 for the Treatment of Advanced NASH in Europe
2023-06-29 06:00U:MNOVNews ReleaseMediciNova Announces Presentation of Results from the Phase 2b Trial of MN-166 (ibudilast) in Alcohol Use Disorder at the 46th Annual Research Society on Alcohol (RSA) Scientific Meeting